Tetraneuron S.L. is a Spanish biotechnology company focused on the development of advanced gene therapies for neurodegenerative diseases, with an initial focus on Alzheimer’s disease. The company originates from leading research in neuroscience and molecular biology, with the aim of addressing the underlying causes of neurodegeneration and developing treatments with disease-modifying potential.
Tetraneuron is led by a team with extensive experience in biotechnology, clinical development, advanced therapies and pharmaceutical partnering, combining top-tier scientific expertise with a strong track record in business development and industrial strategy within the biopharmaceutical sector.
• Development of gene therapies (AAV) for central nervous system diseases
• Translational research in neurodegeneration
• Preclinical and early-stage clinical development
• Intellectual property strategy and partnering
• Public-private collaborations and R&D consortia
Tetraneuron stands out for its upstream and multifactorial approach to neurodegeneration, targeting core disease mechanisms rather than secondary or symptomatic effects. Its therapeutic platform is designed to deliver long-lasting interventions through a single administration, with the potential to transform the treatment of highly prevalent neurodegenerative diseases.
• Pharmaceutical and biotechnology companies
• Life sciences and advanced therapies investors
• Academic institutions and research centers
• Hospitals and clinical networks specialized in neurology
